Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

Panitumumab combined with FOLFOX improves survival and reduces recurrence in RAS/BRAF wild-type locally advanced colon cancer ...

Aditya Shreenivas, MD, MS, discusses findings from the clinical trial supporting the FDA approval of penpulimab in nasopharyngeal carcinoma.

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

T-DXd plus THP led to significant improvements in pathologic complete response in patients with early-stage, HER2+ breast ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...

During a live event, Ahmad Tarhini, MD, PhD, discussed the RELATIVITY-047 trial of nivolumab/relatlimab vs nivolumab alone in ...

The resubmitted biologics license application for narsoplimab in transplant-associated thrombotic microangiopathy has been ...